About AzurRx BioPharma
AzurRx BioPharma is a publicly listed company based in New York (United States) founded in 2014. Recombinant proteins are provided for gastrointestinal disease treatments. AzurRx BioPharma has raised $1.3 million across 10 funding rounds. AzurRx BioPharma has completed 1 acquisition, including First Wave Bio. Its chief executive, as recorded, is James Sapirstein. AzurRx BioPharma offers products and services including Latiglutenase, Capeserod, and Adrulipase. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is FIRST WAVE BIOPHARMA, INC. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
AzurRx BioPharma was established in 2014 in New York, United States, within the biotechnology sector. Recombinant proteins are developed for gastrointestinal disease management. Oral non-systemic biologics are utilized in therapeutic products. The pipeline features MS1819, a recombinant lipase addressing exocrine pancreatic insufficiency for cystic fibrosis and chronic pancreatitis patients, alongside Niclosamide targeted at Covid-19 gastrointestinal infections.
- Headquarters New York, United States
- Stage Public
- SectorsHealthcare
- Website azurrx.com
- Social LinkedIn X Facebook YouTube
- Legal Name First Wave Biopharma, Inc
- Total Equity Funding$1.3M (USD)
in 10 rounds
- Investments & Acquisitions
Products & Services of AzurRx BioPharma
AzurRx BioPharma offers a comprehensive portfolio of products and services, including Latiglutenase, Capeserod, and Adrulipase.
Oral therapy to break up gluten and reduce celiac disease symptoms.
Partial agonist for GI indications like gastroparesis treatment.
Recombinant lipase for exocrine pancreatic insufficiency in patients.
Apps and channels of AzurRx BioPharma
its YouTube channel Entero Therapeutics has 82 subscribers and 30 videos.
Videos from AzurRx BioPharma
The most watched videos on AzurRx BioPharma's YouTube channel, Entero Therapeutics (82 subscribers). Click a video to play it here.
More on Entero Therapeutics.
Funding Insights of AzurRx BioPharma
AzurRx BioPharma has successfully raised a total of $1.3M across 10 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.3M
- Total Rounds 10
- First Round $385,000
(Apr 2014)
All 10 funding rounds of AzurRx BioPharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | Post-IPO | – | – | – | |
| Jul 2020 | $22.43M | Post-IPO | – | – | – |
| Jan 2020 | $6.9M | Post-IPO | – | – | – |
| Feb 2019 | $2M | Post-IPO | – | – | – |
| Jan 2018 | $2.04M | Post-IPO | – | – | – |
| Jun 2017 | $5M | Post-IPO | – | – | – |
| Apr 2017 | $1M | Post-IPO | – | – | – |
| Apr 2016 | $635,000 | Seed | – | – | – |
| Nov 2014 | $284,000 | Seed | – | – | – |
| Apr 2014 | $385,000 | Seed | – | – | – |
People of AzurRx BioPharma
19 people are tracked at AzurRx BioPharma (7 in leadership, 7 in board & advisors, 5 in team).
| Name | Role | Group |
|---|---|---|
James Sapirstein | CEO | Leadership |
Ted Stover | Product Development Director | Leadership |
Mathieu Schué | Head, Laboratory | Leadership |
Amy Chandler | VP, Regulatory Affairs, QA & Compliance | Leadership |
James Pennington | Chief Medical Officer | Leadership |
Catherine Labarca, PHR, SHRM-CP | Director of Human Resources | Leadership |
Nyssa Rodriguez | Executive Administrative Assistant To The Chief Executive Officer | Leadership |
Richard Marlink | Scientific Advisor | Board & advisors |
Alastair Riddell | Director | Board & advisors |
Edward J. Borkowski | Lead Independent Director | Board & advisors |
Brian Feagan | Scientific Advisor | Board & advisors |
Terry Coelho | Director | Board & advisors |
Michael Konstan | Scientific Advisor | Board & advisors |
Anthony Opipari | Scientific Advisor | Board & advisors |
Martin Krusin | SVP, Corporate Development | Team |
Nancy O'Malley | Operations Assistant | Team |
Matt Brieger | Product Development Manager | Team |
Breckon Bauer, CPA | Corporate Controller | Team |
Caitlin Perrone | Controller | Team |
Complete people profiles for AzurRx BioPharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AzurRx BioPharma
AzurRx BioPharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include First Wave Bio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of therapeutics for treating inflammatory bowel disease | firstwavebio.com | Ann Arbor, United States | 2015 | Sep 2021 | $229M |
Complete acquisition details for AzurRx BioPharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of AzurRx BioPharma
5 dated milestones of AzurRx BioPharma across 7 years, from founding to its latest funding, stage changes and deals.
- Founded AzurRx BioPharma is founded.
- Funding First funding round of $385K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
- Acquisition Acquires First Wave Bio.
Competitors of AzurRx BioPharma
AzurRx BioPharma has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of AzurRx BioPharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AzurRx BioPharma
Websites that share an audience with AzurRx BioPharma (azurrx.com).
Websites whose visitors overlap most with AzurRx BioPharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| fiercepharma.com | 100% | #124,066 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as AzurRx BioPharma (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Azurrx Biopharma
Complete news archive for AzurRx BioPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AzurRx BioPharma
AzurRx BioPharma was founded in 2014.
AzurRx BioPharma is headquartered in New York, United States. It is registered at New York, New York, United States.
James Sapirstein is the CEO of AzurRx BioPharma, as recorded in our data.
AzurRx BioPharma is a funded company, having raised a total of $1.3M across 10 funding rounds to date. The company's 1st funding round was a Seed of $385K, raised on Apr 2014.
AzurRx BioPharma was established in 2014 in New York, United States, within the biotechnology sector. Recombinant proteins are developed for gastrointestinal disease management. Oral non-systemic biologics are utilized in therapeutic products. The pipeline features MS1819, a recombinant lipase addressing exocrine pancreatic insufficiency for cystic fibrosis and chronic pancreatitis patients, alongside Niclosamide targeted at Covid-19 gastrointestinal infections.
AzurRx BioPharma's top competitors include BridgeBio, Forge Biologics and Insitro.
AzurRx BioPharma offers Latiglutenase, Capeserod, and Adrulipase.
AzurRx BioPharma has made 1 acquisition, including First Wave Bio.
AzurRx BioPharma operates through First Wave Biopharma, Inc.